Company completes role as fully integrated supplier of beryllium
components for BR2 retrofit
MAYFIELD HEIGHTS, Ohio--(BUSINESS WIRE)--
Beryllium components supplied by Materion Performance Alloys and
Composites, a Materion Corporation (NYSE:MTRN) business, are helping
Belgium's BR2 nuclear test reactor continue operation and contribute to
the world's supply of radiopharmaceuticals.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20160922005843/en/
Beryllium reflector rods made by Materion shine through the center of the partly assembled mock-up for the BR2 matrix refurbishment. Photo provided by SCK-CEN.
In 2013, Belgium's nuclear research center, SCK•CEN, enlisted Materion
to facilitate the production and fabrication of beryllium irradiation
channels required for the 55-year-old reactor's retrofit project.
Launched in 2014, the successful two-year project was completed on June
1, 2016 as the reactor became fully operational once again.
The BR2 reactor plays an important role in producing materials for
nuclear medicine and accounts for nearly one quarter of the world's
production of radiopharmaceuticals used for medical nuclear imaging.
Materion's beryllium rods and reflectors were needed to refurbish
critical components in the BR2. These components are used in many test
reactors because beryllium, with its low atomic number and weight, is
the most efficient neutron donor of any metallic element. In order to
function, nuclear reactors need a concentration of neutrons in the core,
which are created by the uranium in the nuclear fuel, but at an energy
which is not useful for the reactor. Beryllium is capable of reducing
the neutron energy and multiplies the neutrons so the compact reactor
core keeps running. These unique properties make beryllium the material
of choice for nuclear test components at the heart of research reactors.
"BR2 is a major supplier of radioisotopes and the global medical
community relies heavily on its production to diagnose and treat cancer
as well as many other medical conditions," said W. Glenn Maxwell,
President, Materion Performance Alloys and Composites. "It was essential
that we produced high quality materials and delivered them on time to
SCK•CEN so they could keep supply available to meet demand."
According to the World Nuclear Association, the global nuclear medical
market is expected to grow at a CAGR of 9.6% by 2022.
"This is an important market to serve and we're happy we can contribute
to global medical needs with our materials in the nuclear field," said
Maxwell.
Beyond SCK•CEN, Materion supplies a number of nuclear test reactors,
both for materials research and medical isotope production. New
applications, refurbishments and upgrades to other reactors are
scheduled over this year and into 2017, including the RP-10 Reactor in
Peru.
Materion Corporation is headquartered in Mayfield Heights, Ohio. Through
its businesses, Materion supplies worldwide markets with alloy products,
beryllium products, electronic products, precious metal products, and
engineered material systems. Around the world, the company's engineered
materials can be found in technically demanding end-use products within
the telecommunications and computer, automotive electronics, appliance,
industrial components, plastics tooling, optical media, oil and gas,
aerospace and defense, and off-highway and mining equipment markets.
Visit http://www.Materion.com
for more information.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160922005843/en/
Media Contact:
Materion Performance
Alloys
Kurt Eyman, 216-383-4015
Kurt.Eyman@materion.com
or
Investor
Contact:
Materion Corporation
Michael C. Hasychak,
216-383-2863
Mike.Hasychak@materion.com
or
http://www.materion.com
Mayfield
Hts-g
Source: Materion Corporation
News Provided by Acquire Media